Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    22067384 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Conditions: Immunosuppresion;   Thrombocytopenia;   Pancytopenia;   Neutropenia
Interventions: Biological: Anti-thymocyte globulin (rabbit);   Biological: Anti-thymocyte globulin (horse);   Drug: Cyclosporine
2 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath  )
3 Active, not recruiting Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Condition: Aplastic Anemia
Interventions: Drug: Alemtuzumab (Campath-1H);   Drug: Thymoglobulin (r-ATG);   Drug: Cyclosporine (CsA)

Indicates status has not been verified in more than two years